Returns–Not enough quarters yet
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| BNTXBiontech Se | $70.2M | 12.0% | +147.3% |
| Roivant Sciences LtdCUSIP G76279101 | $68.4M | 11.7% | +121.3% |
| Royalty Pharma PLCCUSIP G7709Q104 | $64.8M | 11.0% | +122.3% |
| IONSIonis Pharmaceuticals Inc | $63.3M | 10.8% | +106.4% |
| INSMInsmed Inc | $59.7M | 10.2% | +206.6% |
| REGNRegeneron Pharmaceuticals | $57.8M | 9.8% | +106.8% |
| LEGNLegend Biotech Corp | $34.4M | 5.9% | −9.4% |
| ALNYAlnylam Pharmaceuticals Inc | $34.0M | 5.8% | New |
| NTRANatera Inc | $32.3M | 5.5% | −17.4% |
| GPCRStructure Therapeutics Inc | $23.9M | 4.1% | +252.7% |
| MLYSMineralys Therapeutics Inc | $23.2M | 4.0% | +92.0% |
| VERAVera Therapeutics Inc | $21.4M | 3.6% | New |
| GENBGenerate Biomedicines Inc | $13.9M | 2.4% | +39.4% |
| PRCTProcept Biorobotics Corp | $10.5M | 1.8% | +78.0% |
| AVTXAvalo Therapeutics Inc | $8.7M | 1.5% | New |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| Roivant Sciences LtdCUSIP G76279101 | December 31, 2025 | +63.1% | $68.4M |
| Royalty Pharma PLCCUSIP G7709Q104 | December 31, 2025 | +45.1% | $64.8M |
| GENBGenerate Biomedicines Inc | March 31, 2026 | +35.0% | $13.9M |
| LEGNLegend Biotech Corp | December 31, 2025 | +32.8% | $34.4M |
| NTRANatera Inc | December 31, 2025 | +18.5% | $32.3M |
| GPCRStructure Therapeutics Inc | March 31, 2026 | +11.3% | $23.9M |
| IONSIonis Pharmaceuticals Inc | December 31, 2025 | +0.2% | $63.3M |
| BNTXBiontech Se | December 31, 2025 | −2.3% | $70.2M |
| PRCTProcept Biorobotics Corp | March 31, 2026 | −9.7% | $10.5M |
| REGNRegeneron Pharmaceuticals | December 31, 2025 | −19.2% | $57.8M |
Sold off last quarter
- PFEPfizer Inc was $44.8M
- ARGXArgenx Se was $25.6M
- LLYEli Lilly & Co was $25.1M
- ABVXAbivax Sa was $8.7M
- VRDNViridian Therapeutics Inc was $5.9M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +9.1% | +14.8% |
| March 31, 2026 | +1.3% | −4.6% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Davern Capital Partners, LP Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=2003147&type=13F-HR&dateb=&owner=include&count=40CIK 2003147
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/2003147/000090514826003614/Filed August 13, 2026 · accession 0000905148-26-003614